Review

Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer

Shunsuke Kato

Department of Clinical Oncology, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; katoshun@juntendo.ac.jp; Tel.: +81-3-5802-1543

Abstract: The prognosis of patients with solid tumours has remarkably improved with the development of molecular-targeted drugs and immune checkpoint inhibitors. However, the improvements in the prognosis of pancreatic cancer and biliary tract cancer are delayed compared to other carcinomas, and the 5-year survival rates of distal-stage disease are approximately 10 and 20%, respectively. However, a comprehensive analysis of tumour cells using The Cancer Genome Atlas (TCGA) project has led to the identification of various driver mutations. Evidently, few mutations exist across organs, and basket trials targeting driver mutations regardless of the primary organ are being actively conducted. Such basket trials not only focus on the gate keeper-type oncogene mutations, such as HER2 and BRAF, but also focus on the caretaker-type tumour suppressor genes, such as BRCA1/2, mismatch repair-related genes, which cause hereditary cancer syndrome. As oncogene panel testing is a vital approach in routine practice, clinicians should devise a strategy for improved understanding of the cancer genome. Here, the gene mutation profiles of pancreatic cancer and biliary tract cancer have been outlined and the current status of tumour-agnostic therapy in these cancers has been reported.

Keywords: pancreatic cancer; biliary tract cancer; targeted therapy; solid tumours; driver mutations; agonist therapy

1. Introduction

Pancreatic cancer and biliary tract cancer are malignant tumours with the worst prognosis. By 2020, the number of new cases of pancreatic cancer is estimated to be 57,600 and biliary tract cancer would be 42,810, which accounts for 3.2 and 2.4% of all new cancer cases, respectively. In contrast, the estimated deaths due to pancreatic and biliary tract cancers in 2020 would be 47,050 and 30,160, accounting for 7.8 and 5.0% of all cancer-related deaths in the United States [1].

The poor prognoses of pancreatic and biliary tract cancers are attributable to their low sensitivity to systemic chemotherapy. FOLFIRINOX [2] or combination therapy with gemcitabine and nab-paclitaxel [3] is the first-line therapy for unresectable or metastatic pancreatic cancer, and gemcitabine and CDDP (cisplatin) for biliary tract cancer [4]. These treatments are not based on gene mutation profiles, and the median overall survival is less than one year with either treatment.

However, in recent years, with the advancements in the next-generation sequencing (NGS) technology, the genome profiles of a considerable number of tumour specimens have been markedly improved, thereby making it an era wherein therapeutic targets can be explored based on these data, in a so-called tumour-agnostic or histology-agnostic manner [5–9].

Generally, the amount of DNA required for a gene panel test is 10 to 500 ng, and the proportion of tumour cells contained in the sample is important for ensuring the quality of the test [10]. Previously, it was difficult to collect samples for pancreatic cancer and biliary tract cancer, but with the development of endoscopic ultrasonography (EUS) guided biopsy technology, clinically useful samples can now be collected [11,12]. Furthermore, it has been reported that NGS analysis results are obtained from specimens collected by EUS guided
biopsy, and that the results are comparable to surgical specimens [13,14]. Therefore, it is expected that gene panel tests will be actively performed in pancreatic cancer and biliary tract cancer.

The cancer panel test introduced in clinical practice has led to the identification of druggable mutations in approximately 10% of the pancreatic cancers and 40% of the biliary tract cancers [15]. Therefore, utilisation of tumour multigene NGS is recommended for the detection of actionable alterations in cholangiocarcinoma [16].

Here, we review the genome profiles of pancreatic cancers and biliary tract cancers and the approaches used for the development of drugs for the indicated actionable mutations.

2. Gene Mutation Profiles of Pancreatic Cancers

A considerable number of the gene mutations reported in pancreatic cancer are attributed to KRAS, tumour protein p53 (TP53), SMAD4, and cyclin-dependent kinase inhibitor 2A (CDKN2A), and KRAS mutations account for approximately 90% of the pancreatic cancers [17,18]. The results of all exon analyses and single-nucleotide polymorphism (SNP) arrays using samples obtained from 24 pancreatic cancer patient indicate that pancreatic cancer exhibits an average of 63 genetic changes, most of which are point mutations and such gene mutations are concentrated in 12 cellular signalling pathways [19].

Furthermore, Biankin, AV et al. [20] performed copy number variation (CNV) analysis using exome sequences and arrays of 142 cases of early pancreatic cancer and reported gene mutations in the molecules of the Axon Guidance signal during the embryonic period in addition to the abovementioned 12 cellular signals (slit guidance ligand 2 (SLIT2), roundabout homolog 2 (ROBO2) gene mutation, ROBO1 and SLIT2 copy number decrease, semaphorin 3A (SEMA3A), and plexin-A2 (PLXNA2) copy number increase). The decrease in the expression level of these genes caused by the gene structural mutation is found to be associated with a poor prognosis.

Waddell et al. performed whole-genome analysis and CNV analysis of 100 cases of pancreatic cancer and classified pancreatic cancer based on the pattern of chromosomal structural changes into “stable”, “locally rearranged”, “scattered”, and “unstable” types [21]. Among the locally rearranged types, which account for 30% of all pancreatic cancers, there are cases that show amplification of the protooncogenes such as ERBB2, MET, fibroblast growth factor receptor 1 (FGFR1), cell division protein kinase 6 (CDK6), phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which are likely to be treated by molecular targeted therapies. Additionally, the unstable type, which accounts for 14% of all pancreatic cancers, contains several abnormal DNA repair-related genes. Furthermore, it was reported that cases with abnormalities in these genes were sensitive to platinum-based drugs.

Raphael et al. performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinomas [6]. They reported that abnormalities in genes of the RAS pathway other than KRAS were observed in approximately 60% of the KRAS wild-type pancreatic cancers. The proteomic profiling revealed that the TSC/mTOR (mammalian target of rapamycin) signalling pathway showed increased activation in the KRAS wild-type pancreatic cancer compared to that in the mutant type, and it was considered as one of the molecular targets of the KRAS wild-type pancreatic cancer.

Based on the abovementioned findings, it can be implied that pancreatic cancer is dominated by KRAS mutations or RAS pathway genes, but other gene mutations have also been observed that may be targeted for treatment [22]. In the future, it will be necessary to conduct studies to devise strategies for identification of these patients.

3. Gene Mutation Profiles in Biliary Tract Cancers

Based on the results of comprehensive genetic analysis of biliary tract cancer, the mutant genes of biliary tract cancer constitute a heterogeneous population consisting of
common genetic abnormalities and unique genetic abnormalities in gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma [7–9,23–26].

Li et al. performed a paired analysis with normal specimens of 57 cases of gallbladder cancer and found that gene mutations such as TP53 (47.1%), KRAS (7.8%), and ERBB3 (11.8%) were frequently observed, and patients with ERBB pathway mutations, which comprised 36.8% of the cohort, had a worse outcome [23]. Roa et al. also reported that patients with gallbladder cancer with HER2 overexpression (ERBB2 amplification) demonstrated a worse overall survival [24].

Ross et al. analysed 3320 exons of 182 cancer-related genes and 36 introns of 14 genes in 28 cases of intrahepatic cholangiocarcinoma [25]. Structural abnormalities in AT-rich interaction domain 1A (ARID1A; 36%), isocitrate dehydrogenase 1/2 (IDH1/2; 36%), TP53 (36%), and induced myeloid leukaemia cell differentiation protein (MCL1; 21%) were observed frequently, and fusion genes of FGFR2 and neurotrophic tyrosine kinase (NTRK) were also reported.

Nakamura et al. reported results of the whole-exome analysis of 260 cases of biliary tract cancer (145 cases of intrahepatic cholangiocarcinoma, 86 cases of extrahepatic bile duct cancer, and 29 cases of cholangiocarcinoma) [7]. Compared to the intrahepatic cholangiocarcinoma cases, gallbladder cancer and extrahepatic cholangiocarcinoma cases exhibit a higher frequency of gene mutations and an apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)-associated mutational signature [27]. Significant mutations occurred in 32 genes, including KRAS, PIK3CA, IDH1, NRAS, guanine nucleotide binding protein, alpha stimulating activity polypeptide (GNAS), and ERBB2. Among these, TP53, BRCA1, BRCA2, and PIK3CA were observed as gene mutations common to the biliary tract cancers. Site-specific gene abnormalities of EGFR, ERBB3, phosphatase, and tensin homolog (PTEN), ARID2, mixed-lineage leukaemia protein 2 (MLL2), MLL3, telomerase reverse transcriptase (TERT) promoter mutations were found in gallbladder cancer, PRRKCA or PRRKACB fusion, ELF3, ARID1B in extrahepatic bile duct cancer, and FGFR2 fusion, IDH1/2, EPHA2, and BRCA1 associated protein-1 (BAP1) in intrahepatic bile duct cancer. KRAS, SMAD4, ARID1A, and GNAS mutations were commonly observed in intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma.

Similar to the gene mutation profile of biliary tract cancer, molecular abnormalities related to the RAS pathway are most frequently reported in pancreatic cancer. However, the abnormality of the RAS pathway is only 51.9%, and other pathways or modules include the TGFB-SWI/SNF-MYC module (40.2%), p53 module (33.9%), epigenetic module (29.3%), and RB-cell cycle module (11.7%). Taken together, it can be inferred that nearly 40% of the indicated genes harbour druggable mutations.

Genetic structural mutations associated with the poor prognosis include deletions of CDKN2A/B, ERBB2, TP53, KRAS, ARID1A, and deletion of 7q22.1 [8,9,26]. Nakamura et al. also reported that the subgroup that exhibited the gene expression profile similar to that of the immune system and cytokine activation had a poor prognosis [7].

The major druggable gene mutations are shown in Table 1, and the related clinical trials are shown in Table 2.

**Table 1.** Druggable mutation profiles of pancreatic cancer and biliary tract cancer.

|                      | Pancreatic Cancer | Biliary Tract Cancer |
|----------------------|------------------|----------------------|
| **BRCA1/2**          | ~2%              | Rare                 |
| **MMR (MSI-High)**   | ~2%              | 5–10%                |
| **ERBB2 (amplification)** | <5%       | 1–10%                |
| **BRAF**             | <2%              | 2–5%                 |
| **FGFR**             | Rare             | 5–10%                |
| **IDH1/2**           | Rare             | 5–10%                |
| **NTRK, ALK, ROS1, RET** | <1%   | <1%                  |
Table 2. Clinical trials for druggable mutations in pancreatic cancer and biliary tract cancer.

| Target Therapeutic Agent(s) | Selected Clinical Trials | Status |
|-----------------------------|--------------------------|--------|
| gBRCA1/2 mutation Olaparib | NCT02184195              | Active, not recruiting |
| MSI-H/dMMR Pembrolizumab    | NCT02628067              | Recruiting |
| ERBB2 amplification Trastuzumab and Pertuzumab | NCT02091141 | Active, not recruiting |
| ERBB2 amplification T-DXd, DS-8201a | NCT04482309 | Recruiting |
| IDH1/2 mutation AG-120 (ivosidenib) | NCT02989857 | Active, not recruiting |
| BRAF mutation Dabrafenib and Trametinib | NCT02034110 | Active, not recruiting |
| FGFR2 rearrangement Pemigatinib | NCT03656536 | Recruiting |
| FGFR mutation/fusion Erdafitinib | NCT04083976 | Recruiting |
| FGFR2 fusions/translocations BGJ398 (Infigratinib) | NCT0377302 | Recruiting |
| FGFR2 fusion TAS-120 | NCT02052778 | Active, not recruiting |
| FGFR2 fusion ARQ087 (Derazantinib) | NCT03230318 | Recruiting |
| FGFR1, 2, 3 alteration Debio1347 | NCT01948297 | Terminated |
| NTRK fusion Larotrectinib | NCT02122913, NCT02637687, NCT02576431 | Recruiting |
| NTRK1, NTRK2, NTRK3, ROS1, or ALK RXDX-101 (Entrectinib) | NCT02097810 | Completed |
| KRAS G12C AMG510 | NCT03600883 | Recruiting |

Selected clinical trial identified on clinicalTrials.gov on 31 January 2021.

4. Target Therapy for Germline Mutation

4.1. BRCA1/2

*BRCA1*/*2* is a gene that plays a role in DNA repair during homologous recombination [28,29]. In the cells where homologous recombination repair is not realised due to the deficiency in BRCA1/2 functions, the repair mechanism for DNA double-strand breaks causes genomic instability, resulting in carcinogenesis or cell death [30]. It is also known that cells in which BRCA1/2 does not function are extremely sensitive to DNA-damaging therapy [31–35].

The BRCA1/2 germline mutation has been identified as the causative gene for hereditary breast and ovarian cancer syndrome (HBOC) [36–38] but is also one of the causes for development of hereditary pancreatic cancer. *BRCA1* or *BRCA2* germline mutations reportedly increase the relative risk of pancreatic cancer by 2.26-fold (1.26–4.06) and 3.51-fold (1.87–6.58), respectively [36,37]. It has been reported that 25% of the patients with *BRCA1/2* gene germline mutations are at risk of developing pancreatic cancer, and the lifetime risk of developing pancreatic cancer in patients with *BRCA1/2* gene germline mutations is estimated to be 3–8% [39–42]. Additionally, germline or somatic *BRCA1/2* mutations are associated with 5–9% of the unselected cases of pancreatic cancer [21,43,44].

Since abnormalities in the homologous recombination deficiency (HRD)-related genes are observed in pancreatic cancer, clinical trials to verify the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitors have been conducted in pancreatic cancer patients with germline mutations in *BRCA1/2* [45–48]. The POLO trial was a double-blind placebo-controlled phase III trial that investigated the efficacy of maintenance therapy with olaparib in patients with *BRCA1* or *BRCA2* germline mutations who did not demonstrate exacerbations with platinum-based first-line therapy. A significant increase in progression-free survival was reported in the olaparib group compared to the placebo group (7.4 vs. 3.8 months) [48].

In contrast to pancreatic cancer, it is unclear whether *BRCA1/2* germline mutation is responsible for the risk of developing biliary tract cancer, but it has been reported that *BRCA1* or *BRCA2* germline mutations increase the relative risk of biliary tract cancer by 1.87-fold (0.59 to 5.88) and 4.97-fold (1.50–16.52), respectively [36,37]. Terashima et al. reported cases of three patients with *BRCA1/2* germline mutations (*BRCA1* mutation: *BRCA2* mutation = 1: 2) among eighty Japanese patients with biliary tract cancer who met ≥1 of the following criteria: (1) hereditary breast and/or ovarian cancer (HBOC) testing...
criteria modified for biliary tract cancer; (2) revised Bethesda Guidelines (RBGs) modified for biliary tract cancer (modified RBG); (3) familial biliary tract cancer criteria; (4) criteria for young biliary tract cancer [49].

The effectiveness of PARP inhibitors for biliary tract cancer remains unclear, as fewer patients with BRCA1/2 germline mutations present with biliary tract cancer compared to those presenting with pancreatic cancer. Although effective from a tumour-agnostic perspective, it has been reported that the responsiveness to PARP inhibitors is weak, except for that observed with BRCA mutation-associated tumours [50]. Jonsson et al. also reported that HRD scores [51] tended to increase for BRCA mutation-associated tumours compared to those for non-BRCA mutation-associated types. The HRD score may be more useful as a biomarker for predicting the efficacy of PARP inhibitors than the germline mutations in the BRCA1/2 genes.

4.2. DNA Mismatch Repair (MMR) Genes

The functionality of mismatch repair genes (MMR genes) is crucial for the correction of mismatched nucleotides and insertion/deletion loops that are erroneously incorporated into the newly synthesised strand of DNA during replication, using the parental strand of DNA as a template [52]. Functional loss due to structurally mutated or epigenetically inactivated genes results in the accumulation of replication errors [53]. Microsatellite instability (MSI) is a surrogate marker of predisposition to the mutation that results from impaired MMR gene functions [54].

Among the MMR genes, mutl. homolog 1 (MLH1), mutS homolog 2 (MSH2), MSH6, and PMS2 are reportedly involved in germline pathogenic mutations in Lynch syndrome [55]. Additionally, since epithelial cell adhesion molecule (EPCAM) is located adjacent and upstream to MSH2 and deletion of EPCAM causes decreased expression of MSH2, deletion of the germline EPCAM leads to the development of Lynch syndrome [56]. Furthermore, abnormalities in the functions of MMR-related genes other than those of the abovementioned genes may also result in Lynch syndrome [57].

It has been reported that the patients with germline mutations of the MMR gene demonstrate a cumulative risk of 1.31% of developing pancreatic cancer by the age of 50 years and a cumulative risk of 3.68% of developing pancreatic cancer by the age of 70 years, and the risk is estimated to be 8.6 times more that of the general population [58]. Other reports also suggest that MMR gene germline mutations are a risk factor for pancreatic cancer development [59,60]; however, mutations in the MMR genes in hereditary pancreatic cancer are relatively rare [61].

In contrast, in Lynch syndrome, biliary tract cancer is known as one of the high-risk cancers [62,63]. The risk of developing biliary tract cancer in patients with Lynch syndrome with a genetic aetiology is reported to be standardised incidence ratio (SIR) 9.1; 95% CI, 1.1 to 33 [64]. Microsatellite instability (MSI-High) is observed in approximately 5% of the cholangiocarcinoma and extrahepatic cholangiocarcinoma cases, and nearly 10% of the intrahepatic cholangiocarcinoma and ampullary carcinoma cases [65].

The PD-1 antibody pembrolizumab is highly effective against solid tumours characterised by high MSI or deficiency of MMR [66,67]. In the KEYNOTE-158 study [68], which examined the efficacy of pembrolizumab in patients with solid tumours presenting with MSI other than colorectal cancer, the overall response rate was 34.3% and the median PFS was 4.1 months. This study also included patients with pancreatic and biliary tract cancers, with an objective response rate and progression-free survival of 18.2% and 2.1 months in pancreatic cancers, and 40.9% and 4.2 months in biliary tract cancers.

In 2017, the FDA approved the use of pembrolizumab in patients with solid tumours with high MSI/MMR deficiency, and it is reportedly the first case in which diagnosis does not depend on the primary organ as indicators [69]. Tumour mutation burden (TMB), which is defined as the total number of non-synonymous mutations occurring in the exons of tumour cells, also predicts the effect of pembrolizumab. More than 80% of the cases with high MSI are TMB-high, but only 18.3% of the high-TMB cases are also high-MSI [70].
Goodman et al. also reported that tumours with MS-stable/high-TMB phenotypes exhibit better reactivity to PD-1 antibody than tumours with MS-stable/low or intermediate TMB phenotypes. Since tumours with high TMB are more common than the tumours with a high MSI, the effects of the immune checkpoint inhibitors may be expected in more patients.

5. Targeted Therapy for Somatic Mutations

5.1. ERBB2 (HER2)

ERBB2, also known as HER2, is a gene of receptor tyrosine kinase that constitutes the ERBB family with EGFR, ERBB3, and ERBB4 [71]. HER2 lacks a ligand-binding domain and forms heterodimers with the products from other ERBB family genes to trigger the activation of the MAPK pathway [72,73].

To date, anti-HER2 monotherapy, such as trastuzumab monotherapy, is less effective against HER2-overexpressed pancreatic cancer [74], but combination therapy with HER2 and other ERBB families is promising.

In a pathway basket trial, nine pancreatic cancer patients showing HER2 overexpression or gene amplification by using fluorescence in situ hybridization (FISH) were treated with the combination therapy of trastuzumab and pertuzumab, which is an HER dimerization inhibitor, and a 22.2% objective response rate was obtained [75]. In the same study, eight patients with biliary tract cancer overexpressing HER2 and three patients with ERBB2 structural abnormalities (D277Y, S310F, and A775-G776ins YVMA) were treated with pertuzumab plus trastuzumab, and the response rates were 37.5 and 33.3%, respectively [75,76].

Furthermore, DS-8201 is currently expected to be a new anti-HER2 therapy. DS-8201 is an antibody-drug conjugate (ADC) in which an anti-HER2 antibody is bound to the topoisomerase inhibitor deruxtecan. It is effective in breast cancer [77] and gastric cancer [78] showing HER2 overexpression, and the basket trial for solid cancers showing HER2 overexpression, including pancreatic cancer and biliary tract cancer, is currently in progress (NCT04482309).

5.2. IDH1/2

The isocitrate dehydrogenase (IDH) is an enzyme that catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG). Three subtypes were identified, namely, IDH, IDH1, IDH2, and IDH3. Among these subtypes, point mutations in IDH1 and IDH2 have been reported in gliomas of grade II and III developed from low-grade glioma [79–82]. Further, these genes have been reported to be mutated in acute myeloid leukaemia [83] and prostate cancer [84]. The point mutations recurrently observed in tumour tissue are accumulated on IDH1 R132 and IDH2 R172. These mutants are gain-of-function mutants, which possess enzyme activities necessary for the conversion of α-ketoglutaric acid (α-KG) into D-2-hydroxyglutarate (2-HG). The 2-HG produced by these mutants contributes to DNA methylation by suppressing the enzymatic activity of histone lysine demethylases and causes oncogene activation and tumour suppressor gene inactivation [85]. IDH1/2 mutations are biomarkers with a good prognosis in brain tumours but are not related to the prognosis in biliary tract cancer [26].

Ivosidenib, an inhibitor of IDH1 mutants, and enasidenib, an inhibitor of IDH2 mutants, are reportedly effective against relapsed and refractory acute myeloid leukaemia (AML) with IDH1 and IDH2 mutations, respectively [86–88].

For biliary tract cancer patients with IDH1 mutations, a double-blind phase 3 controlled trial, ClarIDHy, was conducted to evaluate the efficacy of ivosidenib [89]; it was observed that the progression-free survival of the group treated with ivosidenib was significantly prolonged compared to the placebo group (2.7 vs. 1.4 months). Since crossover was allowed in this study, there was a positive trend in the survival of the ivosidenib group, but the difference was not statistically significant. Although the difference in progression-free survival (PFS) is relatively small, it implies that a new treatment option exists for patients with IDH1/2 mutations who constitute a certain proportion of biliary tract cancer cases.
5.3. BRAF

The *BRAF* gene encodes a serine/threonine kinase, which transmits the MAPK signal [90]. *BRAF* and CRAF form dimers using the GTP-bound form of RAS activated by receptor tyrosine kinase (RTKs). The dimerised RAFs activate kinase activities of each other and activate downstream MEKs. *BRAF* mutations found in tumours are classified into three types [91].

The missense mutation that occurs at codon 600 is classified as Class I and is a mutant that demonstrates a remarkable activity even as a monomer, independent of the RAS activity. In contrast, the kinase activity of the Class II mutation exhibits functionality ranging from intermediate to high levels, and the mutation forms a dimer regardless of the RAS-GTP type and results in MEK activation. The Class III mutation loses kinase activity but binds more tightly than the wild-type *BRAF* to RAS-GTP, and their binding to and activation of wild-type CRAF is enhanced, leading to an increased ERK signalling (paradoxical activation). Therefore, Class III *BRAF* mutations often co-occur with RTK overexpression or RAS-activating mutations [92,93]. Since paradoxical activation is also caused by *BRAF* inhibitors [94,95], MEK inhibitors or RTK inhibitors (such as EGFR antibodies) in combination with *BRAF* inhibitors are useful for solid tumours with such *BRAF* mutations [93,96].

Subbiah et al. reported the effect of the combination therapy of the *BRAF* inhibitor and the MEK inhibitor in biliary tract cancer cases with the *BRAF* mutation [97]. In the Rare Oncology Agnostic Research (ROAR) basket trial, combination therapy with dabrafenib and trametinib shows good efficacy against biliary tract cancer cases with *BRAF* V600 mutations, an investigator-assessed overall response of 51%, and an independent reviewer-assessed overall response of 47%.

5.4. FGFR Fusion Genes

Fibroblast growth factor receptor (FGFR) forms a family of receptors and is categorised into four types with a transmembrane tyrosine kinase structure, namely FGFR1, FGFR2, FGFR3, and FGFR4 [98,99]. Structural abnormalities, such as fusion, amplification, and mutation, are observed in various cancer types, especially *FGFR2* and *FGFR3* [100]. *FGFR2* mutations are found in biliary tract cancer (approximately 7%, especially intrahepatic cholangiocarcinoma) and endometrial cancer (approximately 5%), and *FGFR3* mutations are found in bladder cancer (approximately 25%) [101]. Since FGFR structural mutations have been reported recurrently, and in a tumour-agnostic manner, several FGFR inhibitors (antibodies, small molecule compounds) have been developed [102–111]. These drugs exert a high therapeutic effect on the fusion gene among various structural mutations of FGFR. Of these, pemigatinib, an oral inhibitor of FGFR1, FGFR2, and FGFR3, was the earliest FDA-approved drug intended to be used in chemotherapy-resistant cholangiocarcinoma patients with the FGFR2 fusion gene or rearrangement [112].

The FIGHT-202 study was a phase 2 study in which patients with biliary tract cancer who were refractory to prior treatment were grouped according to the presence or absence of FGFR abnormality, and the efficacy of pemigatinib in each group was verified [113]. In this study, the objective response rate was 35.5% in the group with FGFR2 fusion gene or rearrangement, but 0% in the group with other FGFR/FGFR2 mutations and no mutations. The common adverse events were hyperphosphataemia (55%), alopecia (46%), dysgeusia (38%), diarrhoea (37%), and fatigue (32%). Currently, a phase 3 study for unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement is being conducted to compare pemigatinib with gemcitabine plus cisplatin chemotherapy (FIGHT-302; ClinicalTrials.gov, NCT03656536).

At times, resistance mutations are a major clinical problem for molecular-targeted drugs, but a covalent pan-FGFR inhibitor TAS-120 reportedly exerts an antitumour effect against resistance mutations caused by ATP-competitive FGFR inhibitors, such as BGJ398 and Debio 1347 [108].
5.5. Rare Fusion Genes

Since the Bcr-Abl fusion gene was identified as a driver mutation in chronic myelogenous leukaemia, several fusion genes have been identified in malignancies. In solid tumours, since the ALK fusion gene was identified as one of the driver mutations in non-small cell lung cancer [114], it has also been found across cancers of other organs. Additionally, new fusion genes, such as ROS1, RET, and NTRK, have been identified in various solid tumours [115,116].

In pancreatic cancer and biliary tract cancer, these fusion genes are rarely reported. As driver mutations tend to exist in a mutually exclusive manner, these fusion genes are found in cases without other driver mutations. It has also been reported that these fusion genes tend to be found in younger patients. There are some case reports showing the effects of inhibitors targeting these genetic abnormalities [117–121].

Of these fusion genes, targeted therapy for the NTRK fusion gene is the first tissue-agnostic therapy to receive the US FDA approval. [122,123]. The NTRK genes constitute a family of nerve growth factor receptors, and NTRK1, NTRK2, and NTRK3 are genes encoding the tropomyosin-related kinases TRKA, TRKB, and TRKC, respectively. Larotrectinib [124] and entrectinib [125] have been reported to exert markedly high antitumour effects on solid tumours with NTRK fusions (ORR 60–75%) and have already been approved by the FDA and used for treatment.

A noteworthy aspect to be considered in the identification of the fused gene is the presence of a fused gene at the location where driver mutations are not identified in the DNA sequence. As there are restrictions on the probes that can be used in the intron region for the target DNA sequences, targeted hybridization capture-based RNA sequencing or whole transcriptome sequencing may be useful for detecting target genes with unknown fusion partner genes [126].

6. Conclusions

As there is an accumulation of a substantial amount of data on gene mutation profiles of solid tumours, tumour-agnostic treatment based on gene mutations continues to progress, and the usage of personalised medicine is becoming widespread in intractable pancreatic cancer and biliary tract cancer. The remaining challenge in this area is the treatment of KRAS mutant cancers, because KRAS is one of the most frequently mutated genes in pancreatic cancer and biliary tract cancer.

One of the new treatments for the KRAS mutant is Sotorasib (AMG510), which shows a specifically irreversible selective inhibitory effect on KRAS G12C [127,128]. However, the KRAS G12C mutation rate is reported to be high at 13% in lung cancer, and it is only approximately 1% in pancreatic cancer and biliary tract cancer. A novel approach to developing treatments for KRAS mutant cancers, such as those targeting synthetic lethality and metabolism, is expected in the future [129].

Funding: This research received no external funding.

Acknowledgments: This work was supported by JSPS KAKENHI Grant Number 19K07740.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA A Cancer J. Clin. 2020, 70, 7–30. [CrossRef]
2. Conroy, T.; Desseigne, F.; Ychou, M.; Bouché, O.; Guimbaud, R.; Bécouarn, Y.; Adenis, A.; Raoul, J.-L.; Gourgou-Bourgade, S.; De La Fouchardière, C.; et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N. Engl. J. Med. 2011, 364, 1817–1825. [CrossRef]
3. Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N. Engl. J. Med. 2013, 369, 1691–1703. [CrossRef]
4. Valle, J.; Wasan, H.; Palmer, D.H.; Cunningham, D.; Anthoney, A.; Maraveyas, A.; Madhusudan, S.; Iveson, T.; Hughes, S.; Pereira, S.P.; et al. Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. N. Engl. J. Med. 2010, 362, 1273–1281. [CrossRef]
29. Venkitaramanan, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002, 108, 171–182. [CrossRef]

30. Tutt, A.; Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. *Trends Mol. Med.* 2002, 8, 571–576. [CrossRef]

31. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005, 434, 917–921. [CrossRef] [PubMed]

32. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Hellday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature* 2005, 434, 913–917. [CrossRef] [PubMed]

33. Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaiss, H.; Lau, A.; O’Connor, M.J.; et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA1-Mutation Carriers. *N. Engl. J. Med.* 2009, 361, 123–134. [CrossRef]

34. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmana, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; Hubert, A.; et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. *J. Clin. Oncol.* 2015, 33, 244–250. [CrossRef]

35. Abkevich, V.; Timms, K.M.; Hennessy, B.T.; Potter, J.; Carey, M.S.; Meyer, L.A.; Smith-McCune, K.; Broaddus, R.; Lu, K.H.; Chen, J.; et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. *Br. J. Cancer* 2012, 107, 1776–1782. [CrossRef]

36. Thompson, D.; Easton, D.F.; Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. *J. Natl. Cancer Inst.* 2002, 94, 1358–1365. [CrossRef] [PubMed]

37. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J. Natl. Cancer Inst.* 1999, 91, 1310–1316. [CrossRef]

38. Levy-Lahad, E.; Friedman, E. Cancer risks among BRCA1 and BRCA2 mutation carriers. *Cancer* 2016, 124, 375–381. [CrossRef] [PubMed]

39. O'Reilly, E.M.; Lee, J.W.; Lowery, M.A.; Capanu, M.; Stadler, Z.K.; Moore, M.J.; Dhani, N.; Kindler, H.L.; Estrella, H.; Maynard, S.M.; Hubert, A.; et al. Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. *Oncotarget* 2019, 10, 599–612. [CrossRef]

40. Venkitaraman, A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. *Cell* 2002, 108, 171–182. [CrossRef]

41. Nielsen, F.C.; Van Hansen, T.O.; Sørensen, C.S. Hereditary breast and ovarian cancer: New genes in confined pathways. *Int. J. Colorectal Dis.* 2014, 29, 139–145. [CrossRef]

42. Holter, S.; Borgida, A.; Dodd, A.; Grant, R.; Semotuk, K.; Hedley, D.; Dhani, N.; Narod, S.; Akbari, M.; Moore, M.; et al. Association between homologous recombination gene mutations and response to oxaliplatin in pancreatic cancer. *Oncotarget* 2018, 9, 19817–19825. [CrossRef]

43. Thompson, D.; Easton, D.F.; Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. *J. Natl. Cancer Inst.* 2002, 94, 1358–1365. [CrossRef] [PubMed]

44. Bailey, P.; Chang, D.K.; Nones, K.; Johns, A.L.; Patch, A.-M.; Gingras, M.-C.; Miller, D.K.; Christ, A.N.; Bruxner, T.J.C.; Quinn, M.C.; et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016, 531, 47–52. [CrossRef] [PubMed]

45. Shroff, R.T.; Hendrich, A.; McWilliams, R.R.; Geva, R.; Epelbaum, R.; Rolfe, L.; Goblet, S.; Lin, K.K.; Biankin, A.V.; Giordano, H.; et al. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. *JCO Precis. Oncol.* 2018, 2, 1–15. [CrossRef]

46. O'Reilly, E.M.; Lee, J.W.; Lowery, M.A.; Capanu, M.; Stadler, Z.K.; Moore, M.J.; Dhani, N.; Kindler, H.L.; Estrella, H.; Maynard, H.; et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. *Cancer* 2018, 124, 1374–1382. [CrossRef]

47. Tuli, R.; Shiao, S.L.; Nissen, N.; Tighiouart, M.; Kim, S.; Osipov, A.; Bryant, M.; Ristow, L.; Placencio-Hickok, V.; Hoffman, D.; et al. A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. *BioMedicine* 2019, 40, 375–381. [CrossRef]

48. Golan, T.; Hammel, P.; Reni, M.; Van Cutsen, E.; Macarulla, T.; Hall, M.J.; Park, J.O.; Hochhauser, D.; Arnold, D.; Oh, D.Y.; et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N. Engl. J. Med.* 2019, 381, 317–327. [CrossRef]

49. Terashima, T.; Umemoto, K.; Takahashi, H.; Hosoi, H.; Takai, E.; Kondoh, S.; Sakamoto, Y.; Mitsunaga, S.; Ohno, I.; Hashimoto, Y.; et al. Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. *Oncotarget* 2019, 10, 5949–5957. [CrossRef]

50. Bonnem, J.; Forsberg, C.; Schou, M.; Sørensen, T.; Andersen, T.; Nielsen, T.H.; Clausen, K.; Petersen, S.; Holm, P.; et al. Association between homologous recombination gene mutations and response to oxaliplatin in pancreatic cancer. *Oncotarget* 2018, 9, 19817–19825. [CrossRef]

51. Abkevich, V.; Timms, K.M.; Hennessy, B.T.; Potter, J.; Carey, M.S.; Meyer, L.A.; Smith-McCune, K.; Broaddus, R.; Lu, K.H.; Chen, J.; et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. *Br. J. Cancer* 2012, 107, 1776–1782. [CrossRef]

52. Hsieh, P.; Yamane, K. DNA mismatch repair: Molecular mechanism, cancer, and ageing. *Mech. Ageing Dev.* 2008, 129, 391–407. [CrossRef]

53. Kane, M.F.; Loda, M.; Gaida, G.M.; Lipman, J.; Mishra, R.; Goldman, H.; Jessup, J.M.; Kolodner, R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. *Cancer Res.* 1997, 57, 808–811.
Diagnostics 2021, 11, 252

54. Nicola, R.M.; Llor, X.; Pons, E.; Castells, A.; Alenda, C.; Piñol, V.; Andreu, M.; Castellvi-Bel, S.; Payá, A.; Jover, R.; et al. Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair-Deficient Colorectal Tumors. JNCI J. Natl. Cancer Inst. 2007, 99, 244–252. [CrossRef] [PubMed]

55. Desai, T.K.; Barkel, D. Syndromic colon cancer: Lynch syndrome and familial adenomatous polyposis. Gastroenterol. Clin. N. Am. 2008, 37, 47–72. [CrossRef] [PubMed]

56. Sobocińska, J.; Kolenda, T.; Teresiak, A.; Badziąg-Leśniak, N.; Kopczyńska, M.; Guglas, K.; Przybyła, A.; Filas, V.; Bogajewska-Ryłko, E.; Lamperska, K.; et al. Diagnostics of Mutations in MMR/EPICAM Genes and Their Role in the Treatment and Care of Patients with Lynch Syndrome. Diagnostics 2020, 10, 786. [CrossRef]

57. Xavier, A.; Olsen, M.F.; Lavik, L.A.; Johansen, J.; Singh, A.K.; Sjursen, W.; Scott, R.J.; Talseth-Palmer, B.A. Comprehensive mismatch repair gene panel identifies variants in patients with Lynch-like syndrome. Mol. Genet. Genom. Med. 2019, 7, e850. [CrossRef] [PubMed]

58. Kastrinos, F. Risk of Pancreatic Cancer in Families with Lynch Syndrome. JAMA 2009, 302, 1790. [CrossRef] [PubMed]

59. Win, A.K.; Young, J.P.; Lindor, N.M.; Tucker, K.M.; Ahnen, D.J.; Young, G.P.; Buchanan, D.D.; Clendenning, M.; Giles, G.G.; Winship, I.; et al. Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study. J. Clin. Oncol. 2012, 30, 958–964. [CrossRef]

60. Bujanda, L.; Herrera-Villanueva, M. Pancreatic Cancer in Lynch Syndrome Patients. J. Cancer 2017, 8, 3667–3674. [CrossRef] [PubMed]

61. Gargiulo, S.; Torrini, M.; Ollila, S.; Nasti, S.; Pastorino, L.; Cusano, R.; Bonelli, L.; Battistuzzi, L.; Mastracci, L.; Bruno, W.; et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam. Cancer 2009, 8, 547–553. [CrossRef] [PubMed]

62. Mecklin, J.P.; Järvinen, H.J.; Virolainen, M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer 1992, 69, 1112–1114. [CrossRef] [PubMed]

63. Kohlimann, W.; Gruber, S.B. Lynch Syndrome. In GeneReviews®; Adam, M.P.; Ardinger, H.H.; Pagon, R.A.; Wallace, S.E.; Bean, L.J.H.; Stephens, K.; Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2004; Last Update: 4 February 2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK1211/ (accessed on 6 February 2021).

64. Aarnio, M.; Sankila, R.; Puukala, E.; Salovaara, R.; Aaltonen, L.A.; de la Chapelle, A.; Peltomäki, P.; Mecklin, J.P.; Järvinen, H.J. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int. J. Cancer 1999, 81, 214–218. [CrossRef]

65. Silva, V.W.K.; Askan, G.; Daniel, T.D.; Lowery, M.; Klimstra, D.S.; Abou-Alfa, G.K.; Shia, J. Biliary carcinomas: Pathology and the role of DNA mismatch repair deficiency. Chin. Clin. Oncol. 2016, 5, 62. [CrossRef]

66. Le, D.T.; Uram, J.N.; Wang, H.; Bartlett, B.R.; Kemberling, H.; Eyring, A.D.; Skora, A.D.; Luber, B.S.; Azad, N.S.; Laheru, D.; et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015, 372, 2509–2520. [CrossRef] [PubMed]

67. Le, D.T.; Durham, J.N.; Smith, K.N.; Wang, H.; Bartlett, B.R.; Aulakh, L.K.; Lu, S.; Kemberling, H.; Wilt, C.; Luber, B.S.; et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017, 357, 409–413. [CrossRef]

68. Marabelle, A.; Le, D.T.; Ascieri, P.A.; Di Giacomo, A.M.; De Jesus-Acosta, A.; Delord, J.-P.; Geva, R.; Gottfried, M.; Penel, N.; Hansen, A.R.; et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2020, 38, 1–10. [CrossRef] [PubMed]

69. Marcus, L.; Lemery, S.J.; Keegan, P.; Pazdur, R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin. Cancer Res. 2019, 25, 3753–3758. [CrossRef]

70. Goodman, A.M.; Sokol, E.S.; Frampton, G.M.; Lippman, S.M.; Kurzrock, R. Microsatellite- Stable Tumors with High Mutational Burden Benefit from Immunotherapy. Cancer Immunol. Res. 2019, 7, 1570–1573. [CrossRef]

71. Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, S21–S26. [CrossRef] [PubMed]

72. Graus-Porta, D.; Beerli, R.R.; Daly, J.M.; Hynes, N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997, 16, 1647–1655. [CrossRef]

73. Holbro, T.; Beerli, R.R.; Maurer, F.; Koziczek, M.; Barbas, C.F.; 3rd; Hynes, N.E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100, 8933–8938. [CrossRef] [PubMed]

74. Harder, J.; Ihorst, G.; Heinemann, V.; Hofheinz, R.; Moehler, M.; Buechler, P.; Kloeppel, G.; Röcken, C.; Bitzer, M.; Boeck, S.; et al. Multicentre phase II trial of trastuzumab and capcitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br. J. Cancer 2012, 106, 1033–1038. [CrossRef] [PubMed]

75. Hainsworth, J.D.; Meric-Bernstam, F.; Swanton, C.; Hurwitz, H.; Spigel, D.R.; Sweeney, C.; Burris, H.A.; Bose, R.; Yoo, B.; Stein, A.; et al. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase II Multiple Basket Study. J. Clin. Oncol. 2018, 36, 536–542. [CrossRef] [PubMed]

76. Javle, M.M.; Hainsworth, J.D.; Swanton, C.; Burris, H.A.; Kurzrock, R.; Sweeney, C.; Meric-Bernstam, F.; Spigel, D.R.; Bose, R.; Guo, S.; et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. J. Clin. Oncol. 2017. [CrossRef]

77. Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.-B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N. Engl. J. Med. 2020, 382, 610–621. [CrossRef] [PubMed]
87. Stein, E.M.; DiNardo, C.D.; Pollyea, D.A.; Fathi, A.T.; Roboz, G.J.; Altman, J.K.; Stone, R.M.; DeAngelo, D.J.; Patel, M.R.; Collins, R.H.; Mannis, G.N.; Pollyea, D.A.; et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N. Engl. J. Med. 2018, 378, 2386–2398. [CrossRef]

89. Abou-Alfa, G.K.; Macarulla, T.; Javle, M.M.; Kelley, R.K.; Lubner, S.J.; Adeva, J.; Cleary, J.M.; Catenacci, D.V.; Borad, M.J.; Bridgewater, J.; et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020, 21, 796–807. [CrossRef]

90. Wan, P.T.C.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Project, C.G.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell 2004, 116, 855–867. [CrossRef]

93. Yao, Z.; Yaeger, R.; Rodrik-Outmezguine, V.S.; Tao, A.; Torres, N.M.; Chang, M.T.; Drosten, M.; Zhao, H.; Cecchi, F.; Hembrough, T.; et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Cancer Res. 2018, 78, 326–335. [CrossRef] [PubMed]

94. Gibney, G.T.; Messina, J.L.; Fedorenko, I.V.; Sondak, V.K.; Smalley, K.S.M. Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 2013, 10, 390–399. [CrossRef] [PubMed]

95. Yao, Z.; Torres, N.M.; Tao, A.; Gao, Y.; Luo, L.; Li, Q.; de Stanchina, E.; Abdel-Wahab, O.; Solit, D.B.; Poulakis, P.; et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell 2015, 28, 370–383. [CrossRef] [PubMed]

96. Dankner, M.; Lajoie, M.; Moldoveanu, D.; Nguyen, T.T.; Savage, P.; Rajkumar, S.; Huang, X.; Lvova, M.; Protopopov, A.; Vuzman, D.; et al. Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clin. Cancer Res. 2018, 24, 6483–6494. [CrossRef] [PubMed]

97. Subbiah, V.; Lassen, U.; Elez, E.; Italiano, A.; Curigliano, G.; Javle, M.; de Braud, F.; Prager, G.W.; Greil, R.; Stein, A.; et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020, 21, 1234–1243. [CrossRef]

98. Turner, N.; Grose, R. Fibroblast growth factor signalling: From development to cancer. Nat. Rev. Cancer 2010, 10, 116–129. [CrossRef]

99. Brooks, A.N.; Kilgour, E.; Smith, P.D. Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin. Cancer Res. 2012, 18, 1855–1862. [CrossRef]

100. Touat, M.; Ileana, E.; Postel-Vinay, S.; Andre, F.; Soria, J.C. Targeting FGFR Signaling in Cancer. Clin. Cancer Res. 2015, 21, 2684–2694. [CrossRef]

101. OncoKB. Available online: https://www.oncokb.org/ (accessed on 6 February 2021).
102. Guagnano, V.; Kauffmann, A.; Wohrle, S.; Stamm, C.; Ito, M.; Barry, L.; Pournon, A.; Yao, Y.; Li, F.; Zhang, Y.; et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. *Cancer Discov.* 2012, 2, 1188–1193. [CrossRef]

103. Gavine, F.R.; Mooney, L.; Kilgour, E.; Thomas, A.P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M.J.; et al. AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family. *Cancer Res.* 2012, 72, 2045–2056. [CrossRef]

104. Tabernero, J.; Bahleda, R.; Dienstmann, R.; Infante, J.R.; Mita, A.; Italiano, A.; Calvo, E.; Moreno, V.; Adamo, B.; Gazzah, A.; et al. Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors. *J. Clin. Oncol.* 2015, 33, 3401–3408. [CrossRef]

105. Miyano, S.W.; Yamamoto, Y.; Kodama, K.; Miyajima, Y.; Mikamoto, M.; Nakagawa, T.; Kuramochi, H.; Funasaka, S.; Nagao, S.; Sugi, N.H.; et al. E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models. *Mol. Cancer* 2016, 15, 2630–2639. [CrossRef]

106. Javle, M.; Lowery, M.; Shroff, R.T.; Weiss, K.H.; Springerfield, C.; Borad, M.J.; Ramanathan, R.K.; Goyal, L.; Sadeghi, S.; Macarulla, T.; et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. *J. Clin. Oncol.* 2018, 36, 276–282. [CrossRef]

107. Bahleda, R.; Italiano, A.; Hierro, C.; Mita, A.; Cervantes, A.; Chan, N.; Awad, M.; Calvo, E.; Moreno, V.; Govindan, R.; et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. *Clin. Cancer Res.* 2019, 25, 4888–4897. [CrossRef] [PubMed]

108. Goyal, L.; Shi, L.; Liu, L.Y.; de la Cruz, F.F.; Lennerz, J.K.; Raghavan, S.; Leschiner, I.; Elagina, L.; Siravegna, G.; Ng, R.W.S.; et al. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. *Cancer Discov.* 2019, 9, 1064–1079. [CrossRef] [PubMed]

109. Mazzaferrro, V.; El-Rayes, B.F.; Busset, M.D.D.; Cotsoglou, C.; Harris, W.P.; Damjanov, N.; Masi, G.; Rimassa, L.; Personeni, N.; Braiteh, F.; et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. *Br. J. Cancer* 2019, 120, 165–171. [CrossRef]

110. Voss, M.H.; Hierro, C.; Heist, R.S.; Cleary, J.M.; Meric-Bernstam, F.; Tabernero, J.; Janku, F.; Gandhi, L.; Iafrate, A.J.; Borger, D.R.; et al. A Phase I, Open-label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. *Clin. Cancer Res.* 2019, 25, 2699–2707. [CrossRef]

111. Facchinetti, F.; Hollebecque, A.; Bahleda, R.; Loriot, Y.; Olaussen, K.A.; Massard, C.; Friboulet, L. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. *Clin. Cancer Res.* 2020, 26, 764–774. [CrossRef] [PubMed]

112. Hoy, S.M. Pemigatinib: First Approval. *Drugs* 2020, 80, 923–929. [CrossRef]

113. Abou-Alfa, G.K.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.S.; Borad, M.J.; Gallinon, D.; Murphy, A.G.; et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. *Lancet Oncol.* 2020, 21, 671–684. [CrossRef]

114. Soda, M.; Choo, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.-I.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. *Nature* 2007, 448, 561–566. [CrossRef]

115. Stransky, N.; Cerami, E.; Schalm, S.; Kim, J.L.; Lengauer, C. The landscape of kinase fusions in cancer. *Nat. Commun.* 2014, 5, 4846. [CrossRef]

116. Schram, A.M.; Chang, M.T.; Jonsson, P.; Drlon, A. Fusions in solid tumours: Diagnostic strategies, targeted therapy, and acquired resistance. *Nat. Rev. Clin. Oncol.* 2017, 14, 743–758. [CrossRef] [PubMed]

117. Singh, A.D.; Ali, S.M.; Lacy, J.; Hendifar, A.; Nguyen, K.; Koo, J.; Chung, J.H.; Greenbowe, J.; Ross, J.S.; Nikiforova, M.N.; et al. Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma. *J. Natl. Compr. Cancer Netw.* 2015, 13, 555–562. [CrossRef]

118. Pishvaian, M.J.; Bender, R.J.; Halverson, D.; Rahib, L.; Hendifar, A.E.; Mikhail, S.; Chung, V.; Picozzi, V.; Soltal, D.; Blass, E.M.; et al. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. *Clin. Cancer Res.* 2018, 24, 5018–5027. [CrossRef] [PubMed]

119. Drilon, A.; Subbiah, V.; Oxnard, G.; Bauer, T.; Velchetti, V.; Lakhani, N.; Besse, B.; Park, K.; Patel, J.; Cabanillas, M.; et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET -altered cancers. *J. Clin. Oncol.* 2018, 36, 102. [CrossRef]

120. Gu, T.-L.; Deng, X.; Huang, F.; Tucker, M.; Crosby, K.; Rimkunas, V.; Wang, Y.; Deng, G.; Zhu, L.; Tan, Z.; et al. Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma. *PLoS ONE* 2011, 6, e15640. [CrossRef]

121. Demols, A.; Rocq, L.; Charré, M.; Nève, N.D.; Verrellen, A.; Ramadhan, A.; Campenhout, C.V.; Clercq, S.D.; Salmon, I.; D’Haene, N. NTRK gene fusions in biliary tract cancers. *Cancer Discov.* 2016, 15, 33–50. [CrossRef]

122. Deinhardt, K.; Chao, M.V. Trk receptors. *Handb. Exp. Pharm.* 2014, 220, 103–119. [CrossRef]

123. Cocco, E.; Scallitri, M.; Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat. Rev. Clin. Oncol.* 2018, 15, 731–747. [CrossRef]

124. Drilon, A.; Laetsch, T.W.; Kummars, A.; Dubois, S.G.; Lassen, U.N.; Demetri, G.D.; Nathenson, M.; Doebele, R.C.; Farago, A.F.; Pappo, A.S.; et al. Efficacy of Larotrectinib in NTRK-Fusion-Positive Cancers in Adults and Children. *N. Engl. J. Med.* 2018, 378, 731–739. [CrossRef]
125. Doebele, R.C.; Drilon, A.; Paz-Ares, L.; Siena, S.; Shaw, A.T.; Farago, A.F.; Blakely, C.M.; Seto, T.; Cho, B.C.; Tosi, D.; et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020, 21, 271–282. [CrossRef]

126. Benayed, R.; Offin, M.; Mullaney, K.; Sukhadia, P.; Rios, K.; Desmeules, P.; Ptashkin, R.; Won, H.; Chang, J.; Halperny, D.; et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin. Cancer Res. 2019, 25, 4712–4722. [CrossRef]

127. Canon, J.; Rex, K.; Saiki, A.Y.; Mohr, C.; Cooke, K.; Bagal, D.; Gaida, K.; Holt, T.; Krutson, C.G.; Koppada, N.; et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 2019, 575, 217–223. [CrossRef] [PubMed]

128. Hong, D.S.; Fakih, M.G.; Strickler, J.H.; Desai, J.; Durm, G.A.; Shapiro, G.I.; Falchook, G.S.; Price, T.J.; Sacher, A.; Denlinger, C.S.; et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 2020, 383, 1207–1217. [CrossRef] [PubMed]

129. Zeitouni, D.; Pylayeva-Gupta, Y.; Der, C.; Bryant, K. KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers 2016, 8, 45. [CrossRef]